Jaguar Health (NASDAQ:JAGX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report issued on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Trading Up 4.8 %

Jaguar Health stock opened at $0.23 on Tuesday. The company has a 50-day simple moving average of $0.10 and a 200-day simple moving average of $0.18. The company has a debt-to-equity ratio of 6.33, a quick ratio of 1.34 and a current ratio of 2.00. Jaguar Health has a one year low of $0.05 and a one year high of $1.22.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.